| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 467.60 | 2.6% | 37.3% |
| Total Income | 471.98 | 2.3% | 35.8% |
| Expenditure | 382.68 | 7.7% | 29.3% |
| PBT | 89.30 | 15.9% | 73.0% |
| Net Profit | 67.47 | 13.6% | 81.8% |
| OPM | 21.72% | 3.69pp | 4.16pp |
| NPM | 14.30% | 2.63pp | 3.63pp |
| EPS | 20.76 | 10.3% | 94.6% |
Commodity Tailwind Masks Volume Weakness; New Products the Real Story
Balaji delivered 37% revenue and 82% PAT growth, but both are price-driven, not volume-driven. Sequential PAT fell 13.6% despite revenue growth—a sign of margin compression ahead. The call reveals the honest read: a franchise pivoting to higher-margin specialty chemicals, but earnings are at cyclical peak.
₹467.6 Cr
+37.3% YoY | +2.6% QoQ
₹67.5 Cr
+82% YoY | −13.6% QoQ
22%
vs 19% prior year | Guidance met
46.1M tons
−14% YoY | Missed +10-15% guidance
Balaji's Q2 looks like a blowout on the headline: 37% revenue, 82% profit growth. But peel back one layer and the tension reveals itself. Volume growth was just 6% quarter-on-quarter and −14% in the first half year-on-year, well below the 10–15% growth promised in the prior call guidance. The entire profit surge was fueled by a commodity price boom—methanol quadrupled from ₹26–30 to ₹61–62, ammonia tripled from ₹45–50 to ₹85–90—that allowed Balaji to take prices. Then in Q2, despite pushing revenue up 2.6% sequentially, PAT fell 13.6%. Sequential margin compression while topline grows is a flashing light: H2 will feel pressure.
Where the profit really came from
EBITDA margin expanded from 19% to 22%, a +300 basis point swing. Management hit the 22–23% guidance. But here is the honest calculation: raw material costs doubled or tripled; that forced Balaji to raise prices faster than customers expected, which lifted volumes only modestly (6% QoQ) but pulled margins up sharply. This is the definition of cyclical earnings leverage. When methanol and ammonia revert to normalized levels—which management itself acknowledged may happen—margin compression will be swift and large.
37% YoY revenue growth to ₹472 Cr
Delivered ₹467.6 Cr (35.6% vs ₹348 Cr Q2 FY26)
Supported
82% YoY PAT growth to ₹67 Cr
Delivered ₹67.5 Cr (81% vs ₹37 Cr prior year)
Supported
22–23% EBITDA margin sustainable
Q2 delivered 22%; contingent on commodity prices staying elevated
Partially supported
Volume growth 6% QoQ in healthy demand environment
H1 volume −14% YoY; demand weak despite price hikes
Overstated
DME now >50% utilized; ACN ramping to 1,000+ tons/month
DME commissioned Q1, now 50%+ with 7–8 ISO tanks exported; ACN target 1,000–1,200 tons by year-end
Supported
What changed on this call
Multi-year revenue target raised from ₹3,000 Cr (FY28) to ₹3,500–4,000 Cr (FY28–29)
DME capacity utilization upgraded: 50%+ now, target 70–90% by FY28 if BPCL approval
ACN ramp: current 500–1,000 tons/month demand; target 1,000–1,200 tons by year-end
Expansion timelines slipped: Unit-1 brownfield, Unit-2 hydrogen cyanide now year-end target (was July–August)
Volume growth guidance implicitly revised downward: H1 delivered −14% YoY vs +10–15% prior commitment
The bull-bear ledger
82% PAT growth YoY demonstrates operational leverage to commodity cycles
22% EBITDA margin achieved despite −14% H1 volume decline shows pricing power
Three new specialty products (DME, ACN, NMM) entering commercialization; high-margin runway
Specialty Chemicals (BSCL) expansion on track; ₹30–40 Cr revenue by FY28 incremental
Strong cash generation (₹54.5 Cr H1 OCF) funding ₹200+ Cr capex with no capex stress
Revenue growth entirely price-driven; volume −14% H1 YoY indicates weak underlying demand
Sequential PAT fell 13.6% despite 2.6% revenue growth; margin compression starting in H2
Commodity price dependency extreme; guidance assumes prices stay 2–3x normal levels
FY28–29 target ₹3,500–4,000 Cr contingent on multiple assumptions (prices, volumes, execution)
New product revenue contribution Q2 negligible (exports/samples only); FY28 ramp uncertain
FII ownership down 183 basis points YoY (5.0% → 3.17%); institutional conviction waning
Earnings quality: where the pressure lies
Commodity price normalization
HighIf methanol/ammonia revert to historical ₹26–30/₹45–50 levels, EBITDA margin compresses from 22% to 18–20% (−200–400 bps). ₹3,500–4,000 Cr target becomes unachievable without volume recovery; earnings downside material.
Volume recovery stalled
HighH1 −14% YoY despite price surge indicates weak end-market demand (pharma, agro, paint). Balaji missed 10–15% growth from prior guidance; no evidence demand has inflected positively. FY28 volume ramp needed to justify guidance.
New product adoption delays
MediumDME, ACN, NMM revenue contribution Q2 negligible (exports/samples only). BPCL approval for LPG blending, Road Tanker certification 3–4 weeks away; customer trials ongoing. If adoption slower than expected, FY28 revenue unachievable.
Expansion execution slippage
MediumUnit-1 brownfield, Unit-2 hydrogen cyanide already pushed from July–August to year-end. Plant shutdown needed during commissioning (10–15 days per cycle). Further delays compress H2 FY27 revenue and push new capacity monetization to FY28.
Sequential margin compression confirmed
MediumPAT −13.6% QoQ despite +2.6% revenue growth shows margins weakening in Q2 already. If this trend continues into H2, full-year EBITDA margin may miss 22–23% guidance.
How the street is positioned
Balaji's stock has sold off sharply: down 65.62% from its all-time high of ₹5,223.55, now trading at ₹1,796.1. It is below both the 20-day average (₹1,877.6) and the 50-day average (₹2,092.41), though above the 200-day average (₹1,737.19). The RSI of 38.6 is neutral—not oversold. The bigger signal is in ownership: FII holding have dropped 183 basis points year-on-year from 5.0% to 3.17%. This isn't panic selling; it's a quiet reallocation. DII and promoters are steady, but foreign money is reducing conviction. Volume is normal, suggesting no capitulation. The 52-week low was ₹968.1 (now +85.5% above that), and the high ₹2,629.2 (now −31.6% below). The stock's 65% drawdown from ATH is severe, but the valuation remains in the middle of its recent range—not an extreme reversal, not a screaming buy either. The sell-off has been gradual, matching disappointments on volume growth and timeline slips. The institutional trim reflects the same tension the call reveals: strong reported earnings masking weak organic demand and commodity cycle peaks.
1 · Q3 FY27 volume and ACN ramp trajectory
The key to the FY28–29 target is volume recovery. Watch for: Acetonitrile reaching 1,000+ tons/month by year-end; DME utilization holding above 50%; ACN demand from battery electrolyte OEMs. If volumes keep declining, the ₹3,500–4,000 Cr target is fantasy. If they stabilize or recover, the bull case gets legs.
2 · Commodity price normalization and margin guidance
Methanol and ammonia pricing is the lever. If prices stay at ₹61–62 and ₹85–90, Balaji holds 22%+ margins. If they revert toward ₹26–30 and ₹45–50 (even 50% mean reversion), margins compress 200–300 basis points. Q3 earnings will signal whether margin pressure from Q2 extends. Guided range is 22–23%; miss that and FY28 guidance collapses.
3 · Expansion execution and year-end commissioning
Unit-1 brownfield, Unit-2 hydrogen cyanide, Acetonitrile expansion all targeted for year-end. Any delay pushes new capacity revenue into FY28. Successful on-time completion validates execution confidence and unlocks 70–90% utilization by FY28, which is a material earnings driver.
Balaji Amines delivered a solid Q2 operationally—management executed well, costs stayed controlled, margins held firm. But the quarter is a reminder of how cyclical this business is. Reported earnings jump because raw material costs spike, forcing price hikes that flow through to profit. When commodity cycles normalize, earnings will contract just as quickly. The real story is the new product pipeline (DME, ACN, NMM) and the specialty chemicals expansion. If those scale and volume recovers, the long-term thesis holds. If volume keeps falling and commodities revert, the ₹3,500–4,000 Cr target is a mirage.
The stock's 65% drawdown from peak is not unjustified. FII inflows have reversed. The steady message from here is: watch volume, watch commodity prices, watch capex execution. Until one of those inflects positively, hold and wait. The number to track is H1 volume trajectory: if H2 shows recovery toward 10–15% YoY growth, the bull case gains traction. If it stays negative, the near-term stays pressured, and the FY28–29 aspiration becomes a question, not a forecast.
Record margins, volume lags; expansion ramp ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
Hit 22% EBITDA margin vs 22-23% guide; delivered 82% PAT growth; detailed capacity metrics; but missed 10-15% volume growth from prior guidance.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Balaji delivered strong Q2 with 37% revenue and 82% PAT growth driven by commodity margin expansion, not volume growth. Three new products entering commercialization and specialty chemicals expansion on track for year-end completion position for ₹3,500-4,000 Cr by FY28-29. However, sequential PAT decline of 13.6%, volume contraction of 14% H1 YoY, and nascent new product ramp create near-term execution risk.
₹467.6 Cr
Revenue · +37.3% YoY₹67.5 Cr
Reported PAT · +81.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
37% YoY revenue growth to ₹472 Cr
METCall states ₹472 Cr vs ₹348 Cr Q2 FY26 = 35.6% growth; delivered ₹467.6 Cr (+37.3%). Minor consolidation difference.
82% YoY PAT growth to ₹67 Cr
METCall ₹67 Cr vs ₹37 Cr prior year = 81% growth. Delivered ₹67.5 Cr matches.
EBITDA margin 22% vs 19% prior year
METCall ₹106 Cr / ₹472 Cr = 22.5%; prior ₹67 Cr / ₹348 Cr = 19.3%. Aligns with 22-23% guide.
Sequential profitability moderated despite 2.6% revenue growth
METPAT -13.6% QoQ (₹78.1 Cr Q1 to ₹67.5 Cr Q2); revenue +2.6% (₹455.8 Cr to ₹467.6 Cr). Margin compression acknowledged.
DME plant commercialization progressing; 50%+ capacity now
METDME commissioned Q1; now 50%+ utilized, pricing INR110-115. Target 70-90% by FY28 if BPCL approval. Exports ongoing (7-8 ISO tanks).
ACN expected 1,000-1,200 tons/month next year
METCurrently 500-1,000 tons demand; ramp to 1,000-1,200 tons minimum next year from December onwards.
Earnings quality
What changed since the last call
Capacity utilization targets upgraded
UpgradeDME now 50%+ running, targeted 70-90% by FY28 if BPCL approval (vs prior 30-40%). ACN 1,000-1,200 tons/month next year from current 500-1,000 tons.
Multi-year aspiration extended and raised
UpgradePrior ₹3,000 Cr by FY28; now ₹3,500-4,000 Cr for FY28-29. Higher but longer-dated and conditional on commodity prices and volumes.
Expansion timelines revised
DowngradeUnit-1/2 pushed from July-August to year-end due to plant modifications requiring shutdown. Resumption from January; 10-15 days plant offline per modification cycle.
The Q&A
Analysts pressed on DME China dumping risk (management noted prices improved to INR110-115), EDA antidumping timeline (litigation ongoing, opportunity window with pricing), expansion delays (year-end now target, transparent on manufacturing/expansion conflict), and volume drivers for ₹3,500-4,000 Cr (management hedged, cited multiple drivers but no quantified volume trajectory). No evasion; some hedging on sustainability assumptions.
DME pricing & utilization — Akshay Satija, Alpha Invesco
AnsweredUnit-3 at 80%, Unit-4 15-20% (expected 70-80% by FY28). Prices improved to INR110-115. Now >50% utilization.
EDA antidumping impact — Akshay Satija, Alpha Invesco
PartialEDA at 50-60% capacity. Price improved. Litigation ongoing against Finance Ministry for non-implementation. Opportunity window with pricing improvements.
LPG blending approvals for DME — Aditya Iyer, HDFC Securities
AnsweredPESO valves approved. Road Tanker approval in 3-4 weeks. 7-8 ISO tanks already exported. Bulk supplies from BPCL ramp expected post-approval.
₹3,000-4,000 Cr aspiration basis — Kumar Saurabh, Scientific Investing
Partial₹3,500-4,000 Cr for FY28-29 assumes volumes recover as expansions ramp (Acetonitrile, DME, NMM, Specialty Chemicals). Current prices unsustainable; expect normalization but margins stable.
Brownfield expansion delays — Rajiv Rupani, Private Investor
AnsweredCannot run plant and expand simultaneously. Modifications need 10-15 days; now year-end target. Plant offline during shutdown; no sales during that period.
DME/ACN utilization next year — Rajiv Rupani, Private Investor
AnsweredDME >90% if BPCL approval. ACN 50-55% minimum (1,000-1,200 tons/month) from current 500-1,000 tons. Exporting 7-8 ISO tanks; domestic trials ongoing.
DME revenue contribution in Q2 — Diya Jain, Sapphire Capital
AnsweredPESO prevented full ramp. Only exports (7-8 ISO tanks) and domestic samples (20-25 cylinders for aerosol trials). Minimal revenue Q2. Full commercial ramp Q4 FY27 onwards.
Guidance
FY27 standalone implied ₹434 Cr (from Q2 run-rate)
HighQ2 ₹434 Cr standalone; H1 ₹864 Cr consolidated (parent + BSCL). FY27 estimated ₹920-950 Cr if H2 matches H1 run-rate.
FY28-29 target ₹3,500-4,000 Cr consolidated
MediumContingent on: (1) commodity prices normalizing (methanol, ammonia revert to 50% current levels); (2) new products (DME, ACN, NMM) scale to 50-70% capacity; (3) Specialty Chemicals expansions completed on time; (4) volumes return to 10-15% growth range.
EBITDA margin 22-23% sustainable
HighQ2 delivered 22% vs 22-23% prior guide. Achieved via product mix improvement and operational efficiencies despite volume headwinds.
H1 ₹99.4 Cr capex; estimated ₹200+ Cr full FY27
HighUnit-1 brownfield, Unit-2 hydrogen cyanide, Acetonitrile expansion, DME trials. Year-end completion target; capex to taper post-completion.
Risks the call surfaced
Commodity price volatility
HighMethanol prices doubled (INR26 to INR61), ammonia tripled (INR45 to INR85) from historical norms due to Iran-USA tensions. EBITDA and earnings highly sensitive to normalization; sustainability of guidance contingent on elevated prices.
New product adoption risk
MediumDME, ACN, NMM entering commercialization phase. Customer trials ongoing; regulatory approvals (BPCL, Road Tanker, PESO) on critical path. Revenue contribution minimal in Q2; FY28 realization at risk if adoption slower than expected or approvals delayed.
Expansion execution delays
MediumUnit-1 brownfield and Unit-2 hydrogen cyanide expansions already pushed from July-August to year-end. Plant shutdown for modifications during commissioning (10-15 days) risks H2 FY27 revenue loss and delays new product monetization.
Volume recovery slowdown
MediumH1 FY27 sales volume 46.1M tons vs 53.7M tons prior year (-14% YoY). FY26 guidance of 10-15% volume growth not met; only 6% QoQ and -14% H1 indicates significant demand pressure. Recovery dependent on macro/industry demand inflection.
Regulatory/antidumping headwinds
LowEDA antidumping case under litigation; Commerce Ministry recommended implementation, but Finance Ministry non-compliant. Ongoing case may drag; affects EDA pricing leverage and volume recovery timing.
Management
Score 7/10. Clear on operational metrics (capacity utilization, volumes, segment mix) and expansion timelines with detailed timelines. Transparent on regulatory/commodity headwinds. Hedging on volume drivers for ₹3,500-4,000 Cr target; avoided quantifying downside scenarios or normalized pricing impact. Delivered on EBITDA margin guide (22% vs 22-23% prior). Missed volume growth expectations (6% QoQ, -14% H1 YoY vs 10-15% prior guidance). Expansion timelines slipped (July-August to year-end) but explained reasoning and now on track.
1 · Q3 FY27 (Dec 2026)
Acetonitrile ramps 1,000+ tons/month; BPCL LPG blending approval expected; DME/aerosol trials scale
2 · Q4 FY27 (Jan 2027)
Unit-1 brownfield EDA/DETA commercialization; BSCL hydrogen cyanide expansion on stream; ACN full commercial production
3 · FY28 onwards
DME 70-90% capacity if BPCL approval; ACN 50-55%+ utilization; NMM pilot scaling; Specialty Chemicals first revenue contribution
However, sequential PAT decline of 13.6%, volume contraction of 14% H1 YoY, and nascent new product ramp create near-term execution risk.